Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2008 Marzo;52(1) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2008 Marzo;52(1):30-6

ULTIMO FASCICOLOTHE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Rivista di Medicina Nucleare e Imaging Molecolare


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413


eTOC

 

  ADVANCES IN PET - PART II


The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2008 Marzo;52(1):30-6

lingua: Inglese

The role of 124I-PET in diagnosis and treatment of thyroid carcinoma

Lubberink M. 1, Abdul Fatah S. 2, Brans B. 2, Hoekstra O. S. 1, Teule G. J. J. 2

1 Department of Nuclear Medicine and PET Research VU University Medical Centre, Amsterdam, The Netherlands
2 Department of Nuclear Medicine Maastricht University Hospital, Maastricht, The Netherlands


FULL TEXT  ESTRATTI


Iodine-124 is a positron-emitting iodine isotope, enabling measurement of iodine uptake using positron emission tomography (PET). There is a number of situations where the use of 124I-PET/computed tomography (CT) can improve the current clinical practice in the diagnosis and treatment of thyroid cancer. Firstly, 124I-PET/CT can aid in the staging of patients, because of better detection of metastatic disease and measurement of metabolic tumor volume, and thus separate low-risk from high-risk patients. Secondly, the much higher sensitivity and spatial resolution of PET compared to γ scintigraphy can also improve detection of recurrent disease. Furthermore, 124I-PET can be used for patient-specific radioiodine therapy radiation dosimetry. Simultaneous administration of the therapeutic dose of 131I and a tracer dose of 124I allows for accurate measurement of iodine uptake during therapy. The decay scheme of 124I, with few positrons and many γ rays emitted per decay, often simultaneously, poses a challenge to quantitative PET imaging. Improved correction methods and the use of last-generation PET/CT scanners with faster electronics and better energy resolution can overcome this.

inizio pagina